- Home
- MKZR vs ELTX Comparison
MKZR vs ELTX Comparison
Compare MKZR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- ELTX
- Stock Information
- Founded
- MKZR 2012
- ELTX 2011
- Country
- MKZR United States
- ELTX United States
- Employees
- MKZR N/A
- ELTX N/A
- Industry
- MKZR
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- ELTX Health Care
- Exchange
- MKZR Nasdaq
- ELTX Nasdaq
- Market Cap
- MKZR 56.6M
- ELTX 54.6M
- IPO Year
- MKZR N/A
- ELTX 2021
- Fundamental
- Price
- MKZR $2.41
- ELTX $6.25
- Analyst Decision
- MKZR
- ELTX Strong Buy
- Analyst Count
- MKZR 0
- ELTX 3
- Target Price
- MKZR N/A
- ELTX $9.50
- AVG Volume (30 Days)
- MKZR 97.8K
- ELTX 24.8K
- Earning Date
- MKZR 01-01-0001
- ELTX 11-13-2024
- Dividend Yield
- MKZR 7.26%
- ELTX N/A
- EPS Growth
- MKZR N/A
- ELTX N/A
- EPS
- MKZR N/A
- ELTX N/A
- Revenue
- MKZR $17,563,335.00
- ELTX N/A
- Revenue This Year
- MKZR N/A
- ELTX N/A
- Revenue Next Year
- MKZR N/A
- ELTX N/A
- P/E Ratio
- MKZR N/A
- ELTX N/A
- Revenue Growth
- MKZR N/A
- ELTX N/A
- 52 Week Low
- MKZR $1.05
- ELTX $2.96
- 52 Week High
- MKZR $5.50
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- ELTX 62.16
- Support Level
- MKZR N/A
- ELTX $5.50
- Resistance Level
- MKZR N/A
- ELTX $6.55
- Average True Range (ATR)
- MKZR 0.00
- ELTX 0.37
- MACD
- MKZR 0.00
- ELTX 0.09
- Stochastic Oscillator
- MKZR 0.00
- ELTX 82.14
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.